ProKidney Announces Q3 EPS of 12 Cents, Below Consensus Estimate of 14 Cents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Q3 Revenue Performance: ProKidney reported Q3 revenue of $217,000, significantly exceeding the consensus estimate of $44,250.
Phase 2 Study Results: The full results of the Phase 2 REGEN-007 study presented at ASN Kidney Week support the ongoing Phase 3 PROACT 1 study, highlighting the potential of rilparencel as a treatment for advanced chronic kidney disease (CKD) and diabetes.
Efficacy of Rilparencel: In Group 1 of the study, treatment with rilparencel resulted in significant stabilization of kidney function, with 63% of patients meeting key PROACT 1 inclusion criteria.
Focus on PROACT 1 Study: ProKidney remains committed to executing the PROACT 1 study to provide a new treatment option for patients with advanced CKD and diabetes, addressing a significant unmet medical need.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PROK with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PROK
Wall Street analysts forecast PROK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROK is 5.33 USD with a low forecast of 1.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
1 Buy
1 Hold
1 Sell
Hold
Current: 2.100
Low
1.00
Averages
5.33
High
12.00
Current: 2.100
Low
1.00
Averages
5.33
High
12.00
About PROK
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
- Market Transformation: The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations (CDMOs) capturing 67.5% market share, indicating a shift from boutique R&D to scalable bioprocessing infrastructure, which is driving rapid industry growth.
- Surging Demand: The demand for gene and CAR-T therapies has led to CDMO partnerships rapidly expanding viral vector production and GMP-compliant facilities, overcoming previous bottlenecks that constrained commercial access, significantly enhancing market entry capabilities.
- Investment Opportunity: The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, creating an urgent investment window, especially as most emerging biotechs trade at steep discounts.
- Technological Innovation: Avant Technologies is advancing cell encapsulation technology through its joint venture Insulinova with SG Austria, aiming to provide efficient long-term treatment solutions for diabetes patients globally, addressing the immune rejection of implanted cells, thereby laying the groundwork for safe and scalable diabetes therapies.
Continue Reading
Avant Technologies Drives 67.5% Market Share in Cell Therapy Manufacturing
- Market Transformation: The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations (CDMOs) capturing 67.5% market share, marking a transition from boutique R&D to scalable bioprocessing infrastructure that accelerates industry growth.
- Surging Demand: The demand for gene and CAR-T therapies has driven CDMO partnerships to rapidly expand viral vector production and GMP-compliant facilities, overcoming previous bottlenecks that constrained commercial access, significantly enhancing market entry speed.
- Investment Opportunity: The regenerative medicine market is projected to surge from $48.45 billion in 2024 to $403.86 billion by 2032, with cell-based therapies representing the fastest-growing segment, creating an urgent investment window, especially as emerging biotechs trade at steep discounts.
- Technological Innovation: Avant Technologies is advancing cell encapsulation technology through its joint venture Insulinova with SGAustria, aiming to provide effective long-term treatments for diabetes patients globally, addressing the immune rejection of implanted cells, thereby significantly improving patients' quality of life.
Continue Reading